Latham & Watkins LLP represents the underwriters in the offering with a life sciences capital markets led by Bay Area partners Brian Cuneo and John Williams with associates Michelle Lu, Taimi Jacobson and Melinda Vanderburg. Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the bodys immune system to treat patients suffering from cancer and other diseases in the United States. The offering is expected to close on January 11, 2021, subject to customary closing conditions.
In addition, Harpoon Therapeutics has granted the underwriters in the offering a 30-day option to purchase up to 882,352 additional shares of common stock at the public offering price. Harpoon Therapeutics expects that the gross proceeds from the sale of the shares will be approximately $100.0 million, before deducting underwriting discounts and commissions and offering expenses payable by Harpoon Therapeutics. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. T cell engagers are engineered proteins that direct a patient’s. HARP: Get the latest Harpoon Therapeutics stock price and detailed information including HARP news, historical charts and realtime prices. A high-level overview of Harpoon Therapeutics, Inc. Distributed by Public, unedited and unaltered, on 06 June 2022 13:41:01 UTC. Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases.
#Harpoon therapeutics update
Harpoon Therapeutics to Host Pipeline Update Call and Webcast on December 13, 2021. (Nasdaq: HARP), announced the pricing of an underwritten public offering of 5,882,352 shares of its common stock at a price to the public of $17.00 per share. published this content on 01 June 2022 and is solely responsible for the information contained therein. Harpoon Therapeutics Presents Interim Clinical Data from its Ongoing Phase 1/2 Study and New Preclinical Results for BCMA-targeting TriTAC® HPN217 at the 63rd ASH Annual Meeting and Exposition.